Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 100

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 15
Chunk 100
---
 Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited, and Hovione International Limited 10-K001-33093March 3, 201110.10310.30†4th Amendment to Captisol® Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited and Hovione International Limited 10-K001-33093March 3, 201110.10410.31†License Agreement, dated September 3, 1993, between CyDex L.C. and The University of Kansas 10-K001-33093March 3, 201110.10510.32First Amendment to License Agreement, dated February 24, 1998, between CyDex, Inc. and The University of Kansas10-K001-33093March 3, 201110.10610.33†Second Amendment to License Agreement, dated August 4, 2004, between CyDex, Inc. and The University of Kansas 10-K001-33093March 3, 201110.10710.34†Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas 10-K001-33093March 3, 201110.11110.35†Exclusive License Agreement, dated June 4, 1996, between Pfizer, Inc. and The University of Kansas 10-K001-33093March 3, 201110.10810.36†Addendum to Nonexclusive License Agreement, dated December 11, 2001, between CyDex, Inc. and Pfizer, Inc. 10-K001-33093March 3, 201110.1110.37†License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 10-Q001-33093May 8, 201310.210.38†Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 10-Q001-33093May 8, 201310.3

106

10.39†Addendum, dated May